Francisco Javier Novo

Dr. Francisco Javier Novo

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2002 in Blood
Verified
Journal Article
Closed access
PDF file
JMJosé I. Martı́n-Subero
José I. Martı́n-Subero
SGStefan Gesk
Stefan Gesk
LHLana Harder
Lana Harder
TSTakashi Sonoki
Takashi Sonoki
PTPhilip W. Tucker
Philip W. Tucker
RSReiner Siebert
Reiner Siebert
Comparative genomic hybridization studies have shown gains in chromosome region 2p as the most common imbalance in classical Hodgkin lymphoma (cHL). The minimal region of gain contained 2 candidate oncogenes, REL and BCL11A. This study examined the involvement of REL and BCL11A loci in 44 primary cases of cHL by combined immunophenotyping and interphase cytogenetics (FICTION). A median 2p13 copy number above the tetraploid range was detected in 24 (55%) cases. Adjustment for centromere 2 copy number indicated gains of 2p13 in 11 of 31 cHLs (35%) with 8 (26%) high-level amplifications. One cHL displayed selective amplification of the REL locus not affectingBCL11A; another case studied by FICTION and a cHL with cytogenetic 2p change investigated by fluorescence in situ hybridization showed signal patterns suggesting breakpoints in the region spanned by the REL probe. These data indicate thatREL rather than BCL11A may be the target of the 2p13 alterations in cHL.

21 January 2010 in Blood
Verified
Journal Article
Closed access
PDF file
ICIon Cristóbal
Ion Cristóbal
Francisco BlancoFrancisco Blanco
Francisco Blanco
LGLaura Garcia-Orti
Laura Garcia-Orti
NMNerea Marcotegui
Nerea Marcotegui
CVCarmen Vicente
Carmen Vicente
MOMaría D. Odero
María D. Odero
Acute myeloid leukemias (AMLs) result from multiple genetic alterations in hematopoietic stem cells. We describe a novel t(12;18)(p13;q12) involving ETV6 in a patient with AML. The translocation resulted in overexpression of SETBP1 (18q12), located close to the breakpoint. Overexpression of SETBP1 through retroviral insertion has been reported to confer growth advantage in hematopoietic progenitor cells. We show that SETBP1 overexpression protects SET from protease cleavage, increasing the amount of full-length SET protein and leading to the formation of a SETBP1–SET-PP2A complex that results in PP2A inhibition, promoting proliferation of the leukemic cells. The prevalence of SETBP1 overexpression in AML at diagnosis (n = 192) was 27.6% and was associated with unfavorable cytogenetic prognostic group, monosomy 7, and EVI1 overexpression (P < .01). Patients with SETBP1 overexpression had a significantly shorter overall survival, and the prognosis impact was remarkably poor in patients older than 60 years in both overall survival (P = .015) and event-free survival (P = .015). In summary, our data show a novel leukemogenic mechanism through SETBP1 overexpression; moreover, multivariate analysis confirms the negative prognostic impact of SETBP1 overexpression in AML, especially in elderly patients, where it could be used as a predictive factor in any future clinical trials with PP2A activators.

13 September 2002 in Science
Verified
Journal Article
Closed access
PDF file
MEManel Esteller
Manel Esteller
MFMario F. Fraga
Mario F. Fraga
MPMaria F. Paz
Maria F. Paz
ECElias Campo
Elias Campo
DCDolors Colomer
Dolors Colomer
PPPier Giuseppe Pelicci
Pier Giuseppe Pelicci

16 August 2013 in Bioinformatics
Verified
Journal Article
Open access
PDF file
MSMikhail Shugay
Mikhail Shugay
IMIñigo Ortiz de Mendíbil
Iñigo Ortiz de Mendíbil
JVJosé L Vizmanos
José L Vizmanos
FNFrancisco Javier Novo
Francisco Javier Novo
Motivation: Gene fusions resulting from chromosomal aberrations are an important cause of cancer. The complexity of genomic changes in certain cancer types has hampered the identification of gene fusions by molecular cytogenetic methods, especially in carcinomas. This is changing with the advent of next-generation sequencing, which is detecting a substantial number of new fusion transcripts in individual cancer genomes. However, this poses the challenge of identifying those fusions with greater oncogenic potential amid a background of ‘passenger’ fusion sequences. Results: In the present work, we have used some recently identified genomic hallmarks of oncogenic fusion genes to develop a pipeline for the classification of fusion sequences, namely, Oncofuse. The pipeline predicts the oncogenic potential of novel fusion genes, calculating the probability that a fusion sequence behaves as ‘driver’ of the oncogenic process based on features present in known oncogenic fusions. Cross-validation and extensive validation tests on independent datasets suggest a robust behavior with good precision and recall rates. We believe that Oncofuse could become a useful tool to guide experimental validation studies of novel fusion sequences found during next-generation sequencing analysis of cancer transcriptomes. Availability and implementation: Oncofuse is a naive Bayes Network Classifier trained and tested using Weka machine learning package. The pipeline is executed by running a Java/Groovy script, available for download at www.unav.es/genetica/oncofuse.html. Contact:fnovo@unav.es Supplementary information: Supplementary data are available at Bioinformatics online.

28 February 2002 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
JMJosé I. Martín‐Subero
José I. Martín‐Subero
LHLana Harder
Lana Harder
SGStefan Gesk
Stefan Gesk
BSBrigitte Schlegelberger
Brigitte Schlegelberger
WGWerner Grote
Werner Grote
RSReiner Siebert
Reiner Siebert
Many B‐cell malignancies bear chromosomal translocations juxtaposing immunoglobulin (IG) genes with oncogenes, resulting in deregulated expression of the latter. Translocations affecting the IG heavy chain (IGH) locus in chromosomal region 14q32 are most prevalent. However, variant translocations involving the IG kappa (IGK) locus in 2p12 or the IG lambda (IGL) locus in 22q11 occur recurrently in B‐cell neoplasias. No routine methods for the detection of all breakpoints involving IG light chain loci independently of the translocation partner have been described. For this reason, we have designed 2 novel interphase fluorescence in situ hybridization (FISH) assays using differentially labeled probes flanking the IGK and IGL locus, respectively. Based on extensive control studies, the diagnostic thresholds for the detection of breakpoints were set at 0.3% for IGK and 1.4% for IGL. Fifteen cases of B‐cell malignancies with cytogenetically detectable chromosomal abnormalities in 2p11‐14 were investigated with the FISH assay for IGK. Breakpoints affecting the IGK locus were detected in 7 cases including all 4 variant Burkitt's translocations t(2;8)(p12;q24) and a variant BCL2‐associated translocation t(2;18)(p12;q21). Other translocation partners were chromosome bands 7q21 and 16q24. Ten cases with abnormalities in 22q11‐12 were investigated with the FISH assay for IGL. Breakpoints in the IGL locus were diagnosed in 7 cases including both variant Burkitt's translocations t(8;22)(q24;q11) and a t(3;22)(q27;q11) involving the BCL6 locus. Other translocation partners were 2p13‐14, 4q13 and 16p12. Our results show that these FISH assays provide flexible, simple and reliable tools in the diagnosis and characterization of genetic changes in B‐cell malignancies.

26 January 2007 in BMC Genomics
Verified
Journal Article
Open access
PDF file
FNFrancisco Javier Novo
Francisco Javier Novo
IMIñigo Ortiz de Mendíbil
Iñigo Ortiz de Mendíbil
JVJosé L Vizmanos
José L Vizmanos
Despite the importance of chromosomal translocations in the initiation and/or progression of cancer, a comprehensive catalog of translocation breakpoints in which these are precisely located on the reference sequence of the human genome is not available at present. We have created a database that describes the genomic location of 1,225 translocation breakpoints in human tumors, corresponding to 247 different genes, using information from publicly available sources. Junction sequences from reciprocal translocations were obtained from 655 different references (either from the literature or from nucleotide databases), and were mapped onto the reference sequence of the human genome using BLAST. All translocation breakpoints were thus referred to precise nucleotide positions (949 breakpoints) or gene fragments (introns or exons, 276 breakpoints) within specific Ensembl transcripts. TICdb is a comprehensive collection of finely mapped translocation breakpoints, freely available at http://www.unav.es/genetica/TICdb/ . It should facilitate the analysis of sequences encompassing translocation breakpoints and the identification of factors driving translocation events in human tumors.